Tarsus Announces Proposed $100.0 Million Public Offering
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: GlobeNewswire
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering. All shares in the proposed offering are to be sold by Tarsus. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, BofA Securities, Barclays, and Oppenheimer & Co.
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Announces Pricing of Upsized $125.0 Million Public OfferingGlobeNewswire
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Jefferies Financial Group Inc. from $54.00 to $58.00. They now have a "buy" rating on the stock.MarketBeat
- Tarsus to Participate in Upcoming Investor ConferenceGlobeNewswire
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target lowered by analysts at Barclays PLC from $62.00 to $60.00. They now have an "overweight" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $73.00 price target on the stock.MarketBeat
TARS
Earnings
- 2/25/25 - Beat
TARS
Sec Filings
- 3/12/25 - Form 424B5
- 3/11/25 - Form 4
- 3/7/25 - Form 4
- TARS's page on the SEC website